Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation

Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study

The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD. Technical feasibility of the IPS SystemTM will also be evaluated through confirmation of successful application of TLD Therapy.

Inclusion Criteria:

• FEV1 30% to 60%
• FEV1/FVC <70%
• Prior smoker (at least 10 pack years)
• Quit smoking for at least 6 months

Exclusion Criteria:

• Pulmonary hypertension, peripheral edema suggesting CHF or polycythemia
• Prior lung transplant, LVR, LVRS, median sternotomy, bullectomy or lobectomy
• Pulmonary nodule requiring surgery
• Presence of implantable electronic devices
• Active respiratory infection within recent weeks
• COPD exacerbation within recent weeks
• Recent Myocardial infarction (MI)
• Recent and unstable or life threatening arrhythmia
• Malignancy treated with radiation or chemotherapy within the last 2 years
• Presence or clinical diagnosis of other respiratory diseases other than COPD